Serum levels of ACE2 are higher in patients with obesity and diabetes.
Valur EmilssonElias F GudmundssonThor AspelundBrynjolfur G JonssonAlexander GudjonssonLenore J LaunerJohn R LambValborg GudmundsdottirLori L JenningsVilmundur GudnasonPublished in: Obesity science & practice (2020)
ACE2 levels are higher in some patient groups with comorbidities linked to COVID-19 including obesity and T2D and as such may have an emerging role as a circulating biomarker for severity of outcome in the disease.